tradingkey.logo

Dyadic International Inc

DYAI
View Detailed Chart
0.852USD
+0.002+0.26%
Close 02/06, 16:00ETQuotes delayed by 15 min
30.82MMarket Cap
LossP/E TTM

Dyadic International Inc

0.852
+0.002+0.26%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.26%

5 Days

-2.22%

1 Month

-8.42%

6 Months

-13.54%

Year to Date

-9.39%

1 Year

-43.97%

View Detailed Chart

Key Insights

Dyadic International Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 144 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dyadic International Inc's Score

Industry at a Glance

Industry Ranking
144 / 392
Overall Ranking
289 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Dyadic International Inc Highlights

StrengthsRisks
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.50M.
Overvalued
The company’s latest PE is -3.86, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 165.10K shares of this stock.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
7.000
Target Price
+724.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dyadic International Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dyadic International Inc Info

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Ticker SymbolDYAI
CompanyDyadic International Inc
CEOEmalfarb (Mark A)
Websitehttps://dyadic.com/
KeyAI